Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03253848 · ClinicalTrials.gov registry record · NA
Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic Leukemia
A NA study of Acute Promyelocytic Leukemia With PML-RARA and t(15;17), sponsored by ECOG-ACRIN Cancer Research Group.
- Active
- Registry status
- NA
- Development phase
- 202
- Enrollment target
- 20
- Study locations
NCT03253848 is a NA study of Acute Promyelocytic Leukemia With PML-RARA and t(15;17) that is active but no longer recruiting, run by ECOG-ACRIN Cancer Research Group. The registered enrollment target is 202 participants, above the 94-participant average among 3 other Acute Promyelocytic Leukemia With PML-RARA trials with a reported enrollment target (115% higher). The trial reports 20 study locations across 2 states.
The verdict
NCT03253848, a NA study of Acute Promyelocytic Leukemia With PML-RARA and t(15;17), is active but no longer recruiting, sponsored by ECOG-ACRIN Cancer Research Group.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 202 participants
- Enrollment target
- 20
- Study locations
Study Summary
This clinical trial studies how well simplified patient care strategy works in decreasing early death in patients with acute promyelocytic leukemia. Implementing simplified acute promyelocytic leukemia guidelines along with support from acute promyelocytic leukemia experts may decrease deaths and improve survival.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Simplified Patient Care Strategy
Study Locations (20)
California
- Kaiser Permanente-Anaheim - Anaheim
- Kaiser Permanente-Deer Valley Medical Center - Antioch
- Kaiser Permanente-Baldwin Park - Baldwin Park
- Kaiser Permanente-Bellflower - Bellflower
- Kaiser Permanente-Fontana - Fontana
- Kaiser Permanente-Fremont - Fremont
- Fresno Cancer Center - Fresno
- Kaiser Permanente-Fresno - Fresno
- Kaiser Permanente - Harbor City - Harbor City
- Kaiser Permanente-Irvine - Irvine
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- Kaiser Permanente-Cadillac - Los Angeles
- Kaiser Permanente-Modesto - Modesto
- Kaiser Permanente Oakland-Broadway - Oakland
- Kaiser Permanente-Oakland - Oakland
- Kaiser Permanente-Ontario - Ontario
- Kaiser Permanente - Panorama City - Panorama City
- Kaiser Permanente-Rancho Cordova Cancer Center - Rancho Cordova
- Kaiser Permanente-Redwood City - Redwood City
Alaska
- Fairbanks Memorial Hospital - Fairbanks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2017-09-26 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03253848
The ClinicalTrials.gov registry entry for NCT03253848 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 202 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 94-participant average among 3 other Acute Promyelocytic Leukemia With PML-RARA trials with a reported enrollment target (115% higher). The listed sponsor is ECOG-ACRIN Cancer Research Group, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Acute Promyelocytic Leukemia With PML-RARA appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT03253848 reports 20 study locations spanning 2 distinct geographic areas - top geographies include California, Alaska.
Frequently Asked Questions
What is clinical trial NCT03253848 about?
NCT03253848 is a clinical study titled "Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic Leukemia". This clinical trial studies how well simplified patient care strategy works in decreasing early death in patients with acute promyelocytic leukemia. Implementing simplified acute promyelocytic leukemia guidelines along with support from acute promyelocytic leukemia experts may decrease deaths and im...
What is the current status of trial NCT03253848?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 202 participants. The study started on 2017-09-26. Estimated completion is 2027-12-31.
What conditions does trial NCT03253848 study?
This clinical trial studies the following conditions: Acute Promyelocytic Leukemia With PML-RARA, t(15;17).
What interventions are being tested in trial NCT03253848?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Simplified Patient Care Strategy (OTHER).
Who is sponsoring clinical trial NCT03253848?
This trial is sponsored by ECOG-ACRIN Cancer Research Group, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03253848 being conducted?
This trial has 20 study locations across Alaska, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Promyelocytic Leukemia With PML-RARA
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
RECRUITING · Phase 2
-
PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia
ACTIVE NOT RECRUITING · Phase 1
-
Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.